Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein- Barr virus disease after liver transplantation in children

Clinical Infectious Diseases

Volumn 25, Issue 6, 1997, Pages 1344-1349

  Green, Michael ^a   Kaufmann, Mark ^b   Wilson, John ^b   Reyes, Jorge ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EPSTEIN BARR VIRUS; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION;

EID: 0031437776     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516139     Document Type: Article

References (15)

1. Balfour HH, Chace BA, Stapleton JT, Simmons RL. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7.
2. Green M, Tzakis A, Reyes J, et al. Infectious complications of pediatric liver transplantation under FK 506. Transplant Proc 1991;23:3038-9.
3. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg 1994;220:297-309.
4. Swenson PD, Kaplan MH. Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early antigen. J Clin Microbiol 1985;21:669-73.
5. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplant lymphoproliferative disease. N Engl J Med 1992;327:1710-4.
6. Mehta C, Patel N. StatXact statistical software. Cambridge, Massachusetts: Cytel Software, 1992.
7. Collett D. Modelling survival data in medical research. New York: Chapman & Hall, 1994:347.
8. Bowman JA, Green M, Scantlebury V, et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant 1991;5:294-300.
9. Green M, Burckart GJ, Howrie DL, Reyes J, Tzakis A. Acyclovir kinetics and accumulation in pediatric liver transplant recipients (abstract no 1234). In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim). Washington, DC: American Society for Microbiology, 1992:316.
10. Buhles WC Jr, Mastre BJ, Tinker AJ, Strand V, Koretz SH, the Syntex Collaborative Ganciclovir Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988;10 (suppl 3):S495-506.
11. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing high dose oral acyclovir to ganciclovir for the prevention of cytomegalovirus infection after liver transplantation. Transplantation 1994;58:779-85.
12. Freise CE, Pons V, Lake J, et al. Comparison of three regimens for cytomegalovirus prophylaxis in 147 liver transplant recipients. Transplant Proc 1991;23:1498-500.
13. Winston DJ, Wirin D, Snaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995;346:69-74.
14. Pescovitz M, Gane E, Saliba F, et al. Efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients [abstract no H4]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996:163.
15. Green M, Wilson J, Nalesnik M, et al. Incidence of posttransplant lymphoproliferative disease (PTLD) among organ transplant recipients under tacrolimus immunosuppression [abstract no H140]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:204.